COMPLEX GENERICS: OPPORTUNITIES & CHALLENGES
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 3
Abstract
Now a day, big pharmaceutical companies with sustainable revenues are more interested in complex products to minimize competitions. In line with the originator companies, many generic companies are also focusing on complex products, either a specialized dosage form of already approved product or generic version of approved specialized products i.e. complex generics. Inherent ‘complexity’ involved in such specialized products insulates fierce competition and are considered as potential opportunities with high revenues. U.S FDA approved specialized products with proprietary technologies, such as nanoparticles, microspheres or liposomes are most promising dosage forms. These dosage forms are proven to be safer, while providing better efficacy as compared to historically approved simpler dosage forms, by ensuring targeted delivery of drug towards the infected cells. In the era of recent scientific advances, many generic companies are investing in abundance for the development of complex generics in the segment of targeted delivery systems like liposomes, therapeutic nanoparticles for treatment of various diseases such as cancers, inflammatory disorders, infectious and cardiovascular diseases. Despite potential opportunities reside in developing complex generics in terms of safety, efficacy and high revenue, no authoritative article has enlightened the challenges relating to regulatory, scientific, clinical, intellectual property (IP) and commercialization of complex generics. The present article makes an attempt to address the challenges involved in a regulatory approval of such complex generics involving potential opportunity with low competition.
Authors and Affiliations
Vure Prasad, Kale Pooja
Keywords
Related Articles
- EP ID EP336989
- DOI 10.22270/ijdra.v4i3.184
- Views 104
- Downloads 0
Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review
In the healthcare industry, the biggest challenges are cancer. However, there are several drugs are available for the treatment of cancer. In these treatments cure cancer affecting the collateral toxicity to healthy cell...
GERMANY PATENT SYSTEM – AN OVERVIEW
Patent is one of the intellectual property rights, by which the innovator gets exclusive rights or legal monopoly grated to an individual or a firm to make use or sell or reproduce and excluding others from doing so. The...
RISING AIR POLLUTION: DEMAND ACTION-DRIVEN ADVOCACY AND BEHAVIOUR CHANGE FOR HEALTHER LIVES
Air pollution is a major environmental health problem affecting the developing and the developed countries alike. The effects of air pollution on health are very complex as there are many different sources and their indi...
CONDUCIVE ENVIROMENT FOR FOSTERING INDIA SPECIFIC INNOVATION: NEW MEDICAL DEVICE RULES 2017
The medical technology sector in India valued at approximately $ 10 billion in 2015 at end consumer prices and is growing at 10-12 percent annually. Currently, the Indian medical devices industry represents just over 2 p...
STATUS OF A T POLYMORPHISM IN EXON II OF KINASE INSERT DOMAIN GENE IN WOMEN WITH PREMATURE OVARIAN FAILURE
Ovarian failure is defined as cessation of ovarian function under the age of 40 and it is characterized by amenorrhea hypo estrogenism and elevated gonadotrophin serum levels leading to infertility. Ovarian failure affec...